Fierce Pharma

CMS makes it official, codifying Medicare drug price negotiations established under IRA

Moderna swings to profit as momentum for cancer vaccine builds

Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy

Revolution Medicines’ pancreatic cancer drug has stunning commercial debut

Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals

Novo Nordisk shares jump 6% after lifting 2026 outlook on obesity-drug demand

Pfizer Bets on Cancer and Weight-Loss Drugs in Post-Pandemic Second Act

AstraZeneca CEO strikes bullish tone on pipeline as stock rallies

Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

RFK Jr. takes shortcut to make some unapproved peptides available for use

Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim

Free Meals and Other Perks From Big Pharma Really Do Sway Doctors, Review Finds

Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run

Viatris to Buy Pacira BioSciences for $1.65 Billion

High cost of GLP-1s drives some to seek cheaper, unregulated versions

Could carpal tunnel symptoms be a sign of something else? Amyloidosis found during surgery

AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

America Wants to Make More Generic Drugs. India Shows Why That’s Hard.

Pharma's new top lobbyist is former Majority Leader Eric Cantor

Eli Lilly CEO reveals astonishing shift in GLP-1 pill market

European drugmakers say they are ‘losing ground’ to US and Chinese rivals

Trump calls for some childhood vaccines be split into smaller doses

Why Novo Stock Is Dropping After Drugmaker Unveils Ambitious Growth Plan

EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say

FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease

Vera kidney drug Trutakna shows strong final results in Phase 3 trial

Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters

Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped

FDA announces nationwide recall of epinephrine injections after reports of cracked vials

Summit Packs A Punch For Merck's Keytruda

CBER official overruled review team’s rejection of new Replimune melanoma drug

ARPA-H awards $125M for manufacturing custom RNA therapies on demand

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers

Trump’s new drug pricing deals aim to slash prescription costs, sparking a wave of coverage on potential savings.

In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs

US FDA approves Lilly's Mounjaro to reduce cardiovascular risk

FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients

The Race to Develop More Medicines Like the New Pancreatic Cancer Drug

The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify

Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg

McKesson strikes $2.25 billion Precision Medicine deal in clinical research bets

RFK Jr. may upend how vaccine recommendations are categorized

FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class

Bristol Myers to build $2.3 billion manufacturing site in Houston

In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

FDA approves Replimune melanoma drug previously rejected twice

The Race to Come Up With the Next Big Sleep Drug

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments

F.D.A. Approves Moderna’s mRNA Flu Vaccine

Novo Nordisk Stock Bounces Back After Surprise Earnings Report

Amgen drops ph. 1 obesity drug, upping pressure on MariTide

Lipfendra vs statins: How these cholesterol-lowering drugs compare

Pfizer Covid Pill Revenue Plunges 95%. That’s Just One Reason the Stock Is Slipping.

AstraZeneca Shares Fall on Deal Talks With Bristol-Myers

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK is implementing a $2.5 billion, three-year restructuring initiative to prioritize late-stage drug development and reorganize its research operations.